<?xml version="1.0" encoding="UTF-8"?><lom xmlns="http://ltsc.ieee.org/xsd/LOM" xmlns:lomfr="http://www.lom-fr.fr/xsd/LOMFR" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://ltsc.ieee.org/xsd/LOM http://www.lom-fr.fr/xsd/lomfrv1.0/std/lomfr.xsd">
<general>
<identifier>
<catalog>Canal-U_Ocms</catalog>
<entry>11453</entry>
</identifier>
<title><string language="fre"><![CDATA[Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods for Imaging Approaches, IVUS and IMT (Wolfgang KOENIG)]]></string></title>
<language>ENG</language>
<description>
<string language="fre"><![CDATA[MODIGLIANI Workshop 2 - Friday November 30, 2012 :
ATHEROSCLEROSIS IMAGING IN CLINICAL TRIALS
Facilitating the discovery of effective therapies
Chairpersons: Jagat NARULA, New York, USA - Ahmed TAWAKOL, Boston, USA
Webcast: Bart STAELS, Lille, FRA
Phase III clinical endpoint trials evaluating treatments for atherosclerosis typically require very large sample sizes, cost hundreds of millions of dollars and historically have had very low success rates. As a result, few new therapies that attenuate the progression of atherosclerosis have been identified in over 30 years (since the discovery of statins). 
Nearly a decade ago, in recognition of the low success of Phase III trials, regulatory agencies called for the adoption of new biomarkers or surrogate endpoints to enhance the rate of clinical development. To that end, several cardiovascular imaging technologies have gone through evolutionary cycles of validation over the past decade and several have demonstrated promise as clinical tools and as clinical trial biomarkers.
With the rapid development and implementation of these imaging approaches, it is important to delineate the opportunities and limitations associated with these tools. In particular, it is essential to identify imaging biomarkers that might accurately predict eventual clinical success based on the observed changes in the atherosclerotic imaging measurements. With such tools as gatekeepers, only those treatments with proven efficacy during Phase II trials would be promoted to Phase III
with the expectation of high likelihood of success in the clinical endpoint trials. By enhancing the success rate of Phase III clinical trials, use of these imaging tools have the potential to accelerate the discovery of treatments for atherosclerosis.
Session program:
Overview: Why are imaging endpoints needed in CV clinical trials
Speaker: Jagat NARULA, New York, USA
Well Established Methods for Imaging Approaches: IVUS and IMT
Speaker: Jean-Claude TARDIF, Montréal, CAN
Discussant: Wolfgang KOENIG, Ulm, GER
Coronary CTA in clinical trials
Speaker: Udo HOFFMANN, Boston, USA
MRI imaging in clinical trials
Speaker: Zahi FAYAD, New York, USA
Discussant: Robin CHOUDHURY, Oxford, GBR
PET-CT imaging in clinical trials
Speaker: Ahmed TAWAKOL, Boston, USA
Discussant: James RUDD, Cambridge, GBR]]></string></description>
<keyword><string language="fre"><![CDATA[Maladies cardiovasculaires]]></string></keyword>
<lomfr:documentType>
<lomfr:source>LOMFRv1.0</lomfr:source>
<lomfr:value>image en mouvement</lomfr:value>
</lomfr:documentType>
</general><lifeCycle>
<contribute>
<role>
<source>LOMv1.0</source>
<value>content provider</value>
</role>
<entity><![CDATA[BEGIN:VCARD
VERSION:3.0
CLASS:PUBLIC
REV:2021-07-06 15:41:51
FN:Canal U/3S - CERIMES
N:Canal U/3S - CERIMES;;;;
URL;TYPE=work:https://www.canal-u.tv/auteurs/canal_u_3s_cerimes
ROLE:content provider
TZ:+0200
END:VCARD
]]></entity>
<date><dateTime>2012-11-30</dateTime></date>
</contribute>
<contribute>
<role>
<source>LOMv1.0</source>
<value>publisher</value>
</role>
<entity><![CDATA[BEGIN:VCARD
VERSION:3.0
CLASS:PUBLIC
REV:2021-07-06 15:41:51
FN:Canal U/3S - CERIMES
N:Canal U/3S - CERIMES;;;;
URL;TYPE=work:https://www.canal-u.tv/auteurs/canal_u_3s_cerimes
ROLE:publisher
TZ:+0200
END:VCARD
]]></entity>
<date><dateTime>2012-11-30</dateTime></date>
</contribute>
<contribute>
<role>
<source>LOMv1.0</source>
<value>author</value>
</role>
<entity><![CDATA[BEGIN:VCARD
VERSION:3.0
CLASS:PUBLIC
REV:2021-07-06 15:41:51
FN:Wolfgang KOENIG
N:KOENIG;Wolfgang;;;
URL;TYPE=work:https://www.canal-u.tv/auteurs/koenig_wolfgang
ROLE:author
NOTE:KOENIG Wolfgang, Ulm, GER&lt;br&gt;Wolfgang Koenig, MD, PhD, FRCP, FESC, FACC, FAHA is a Professor of Medicine and Cardiology at the University of Ulm Medical School, Ulm, Germany. He is Board certified in internal medicine, cardiology, and in intensive care medicine with special interest in invasive and interventional cardiology. At present he serves as a Consultant in Cardiology, and is the Director of the Preventive Cardiology Program and the Clinical Trial Unit (CTU) at the Department of Internal Medicine II - Cardiology of the University of Ulm Medical Center. Dr. Koenig`s research interests involve the molecular basis of atherothrombogenesis including genomics, metabolomics, and other technologies. Further interests include type 2 diabetes, the metabolic syndrome, the clinical pharmacology of cardiovascular active compounds, and the clinical epidemiology of cardiovascular disorders, focusing on the identification and evaluation of new biomarkers for cardiometabolic diseases. Dr. Koenig has published more than 500 research papers and reviews. He has an H-Index of 60. He is a member of the Editorial Board of Clinical Chemistry and Associate Editor of Atherosclerosis. Presently he serves on the Steering Committee of various large international randomized clinical trials testing innovative targets in cardiovascular medicine. 
TZ:+0200
END:VCARD
]]></entity>
<date><dateTime>2012-11-30</dateTime></date>
</contribute>
</lifeCycle>
<metaMetadata>
<metadataSchema>LOMv1.0</metadataSchema>
<metadataSchema>LOMFRv1.0</metadataSchema>
</metaMetadata>
<technical>
<format>video/mp4</format>
<location><![CDATA[https://www.canal-u.tv/video/canal_u_medecine/cardiovascular_clinical_trialists_cvct_forum_paris_2012_workshop_2_well_established_methods_for_imaging_approaches_ivus_and_imt_wolfgang_koenig.11453]]></location>
<location><![CDATA[https://streaming-canal-u.fmsh.fr/vod/media/canalu/videos/cutms/cardiovascular.clinical.trialists.cvct.forum.a.paris.2012.workshop.2.well.established.methods.for.imaging.approaches.ivus.and.imt.wolfgang.koenig._11453/26_modigliani_workshop2_wolfgangkoenig_std.mp4]]></location>
<location><![CDATA[https://streaming-canal-u.fmsh.fr/vod/media/canalu/videos/cutms/cardiovascular.clinical.trialists.cvct.forum.a.paris.2012.workshop.2.well.established.methods.for.imaging.approaches.ivus.and.imt.wolfgang.koenig._11453/26_modigliani_workshop2_wolfgangkoenig_bd.mp4]]></location><location><![CDATA[https://streaming-canal-u.fmsh.fr/vod/media/canalu/videos/cutms/cardiovascular.clinical.trialists.cvct.forum.a.paris.2012.workshop.2.well.established.methods.for.imaging.approaches.ivus.and.imt.wolfgang.koenig._11453/26_modigliani_workshop2_wolfgangkoenig_hd.mp4]]></location>
<size>62768216</size>
<duration><duration>PT0H15M3S</duration></duration>
</technical>
<educational>
<learningResourceType>
<source>LOMv1.0</source>
<value>lecture</value>
</learningResourceType>
<context>
<source>LOMv1.0</source>
<value>higher education</value>
</context>
<context>
<source>LOMv1.0</source>
<value>formation continue</value>
</context>
</educational>
<rights>
<cost>
<source>LOMv1.0</source>
<value>no</value>
</cost>
<copyrightAndOtherRestrictions>
<source>LOMv1.0</source>
<value>no</value>
</copyrightAndOtherRestrictions>
<description>
<string language="fre"><![CDATA[Droits réservés à l'éditeur et aux auteurs. 
]]></string>
</description>
</rights>
<relation>
<kind>
<source>LOMv1.0</source>
<value>ispartof</value>
</kind>
<resource>
<identifier>
<catalog>URI</catalog>
<entry>https://www.canal-u.tv/producteurs/canal_u_medecine/cardiologie/colloque_et_evenement/cvct</entry>
</identifier>
<description>
<string language="fre"><![CDATA[CVCT 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012]]></string>
</description>
</resource>
</relation>
<classification>
<purpose>
<source>LOMv1.0</source>
<value>discipline</value>
</purpose>
<taxonPath>
<source>
<string language="fre"><![CDATA[Universités Numériques Thématiques 2009 http://www.universites-numeriques.fr]]></string>
</source>
<taxon>
<id/>
<entry>
<string language="fre"/>
</entry>
</taxon>
</taxonPath>
</classification>
<classification>
<purpose>
<source>LOMv1.0</source>
<value>discipline</value>
</purpose>
<taxonPath>
<source>
<string language="fre">CDD 22e éd.</string>
<string language="eng">DDC 22nd ed.</string>
</source>
<taxon>
<id>616.1</id>
<entry>
<string language="fre"><![CDATA[Maladies de l'appareil cardio-vasculaire]]></string>
</entry>
</taxon>
</taxonPath>
</classification> </lom>